EUVIMEDEUVIMED entdecken
Leserbrief

Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China

Yihui Chen, Qiaozhi Cao, Cong Peng, Bingjing Zhou, Yu Jiang, Xiang Chen, Jie Li

Frontiers of Medicine · 2024

DOI: 10.1007/s11684-024-1063-9 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Frontiers of Medicine, 2024. Verfasst von Yihui Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansProspective StudiesChinaFemaleMaleAdultTreatment OutcomeJanus Kinase 1AdolescentPyrimidinesSeverity of Illness IndexYoung AdultPyrazolesJanus Kinase InhibitorsSulfonamidesMiddle AgedAzetidinesNitrilesPiperidinesChild

Substanzen

Janus Kinase 1PyrimidinestofacitinibPyrazolesJanus Kinase InhibitorsSulfonamidesruxolitinibAzetidinesbaricitinibNitriles

Autor:innen und Institutionen

  • Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China.
  • Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, 410008, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China.
  • Furong Laboratory, Changsha, 410008, China.
  • Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China. xylijie@csu.edu.cn.
  • Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, 410008, China. xylijie@csu.edu.cn.

Zitieren

APA

Chen, Y., Cao, Q., Peng, C., Zhou, B., Jiang, Y., Chen, X., & Li, J. (2024). Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China. Frontiers of Medicine. https://doi.org/10.1007/s11684-024-1063-9

Vancouver

Chen Y, Cao Q, Peng C, Zhou B, Jiang Y, Chen X, et al. Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China. Frontiers of Medicine. 2024. doi:10.1007/s11684-024-1063-9

BibTeX
@article{Chen2024,
  author = {Chen, Yihui and Cao, Qiaozhi and Peng, Cong and Zhou, Bingjing and Jiang, Yu and Chen, Xiang and Li, Jie},
  title = {Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China},
  journal = {Frontiers of Medicine},
  year = {2024},
  doi = {10.1007/s11684-024-1063-9}
}
Kostenlos starten →